The EC’s inquiry into the pharmaceutical industry and moves to usher in a region-wide patent court could revolutionise Europe’s drug market. Bird & Bird’s Gerry Kamstra reports
Two recent developments at European Union (EU) level are likely to have an influence on pharmaceutical patent litigation; the first in a more imminent fashion than the second. In January 2008 the European Commission (EC) launched a sector inquiry into EU pharmaceutical markets because information relating to innovative and generic medicines suggested that competition may be restricted or distorted.
